<DOC>
	<DOCNO>NCT00131742</DOCNO>
	<brief_summary>This study conduct compare effectiveness safety telbivudine ( LdT ) lamivudine Chinese adult .</brief_summary>
	<brief_title>Telbivudine Versus Lamivudine Chinese Adults With Compensated Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Documented clinical history compatible chronic hepatitis B infection Other protocoldefined inclusion criterion may apply Patient pregnant breastfeeding Patient coinfected hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) HIV Patient previously receive lamivudine investigational antiHBV nucleoside nucleotide analog Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>